Qyuns Therapeutics Co., Ltd. (HKG:2509)
Hong Kong · Delayed Price · Currency is HKD 19.38
+0.47 (2.49%)
At close: Mar 27, 2026
Qyuns Therapeutics Revenue
In the year 2025, Qyuns Therapeutics had annual revenue of 806.96M CNY with 408.18% growth. Qyuns Therapeutics had revenue of 206.49M in the half year ending June 30, 2025.
Revenue
806.96M CNY
Revenue Growth
+408.18%
P/S Ratio
4.85
Revenue / Employee
2.39M CNY
Employees
337
Market Cap
4.35B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 806.96M | 648.17M | 408.18% |
| Dec 31, 2024 | 158.79M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 9.66M | -11.69M | -54.74% |
| Dec 31, 2021 | 21.35M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Viva Biotech Holdings | 2.01B |
| AIM Vaccine | 1.38B |
| BioDlink International Company | 831.99M |
| Shandong Boan Biotechnology | 829.27M |
| Medtide | 546.29M |
| Mirxes Holding Company | 166.32M |
| Antengene Corporation | 117.22M |
| Jacobio Pharmaceuticals Group | 59.56M |